Skip to content
drillr.ai
Sign up

ILMN

Illumina, Inc.

NASDAQ · Healthcare · Medical - Diagnostics & Research · US

$217.37
−1.94%
Ask drillr

  • Aug 24, 2026, 08:04 UTC

    Biondo Investment Advisors LLC acquired a new minority stake in Illumina, Inc. by purchasing 10,630 shares valued at approximately $1.87 million, as disclosed in a 13F filing.

    Source:

  • Aug 23, 2026, 08:32 UTC

    Allworth Financial LP acquired a new position in Illumina, Inc. by purchasing 5,976 shares valued at approximately $1,051,000 in the second quarter, as disclosed in its 13F filing.

    Source:

  • Aug 13, 2026, 00:00 UTC

    Illumina, Inc. entered into a new $1 billion senior unsecured five-year revolving credit facility with a syndicate of lenders led by Bank of America, N.A., JPMorgan Chase Bank, N.A., Citibank, N.A., and Goldman Sachs Bank USA, and terminated its existing 2023 credit agreement.

  • Aug 6, 2026, 05:50 UTC

    Illumina announced the launch of the MiSeq i100 Series-CN in China and delivered the first batch of locally manufactured products to customers.

    Source:

  • Jul 30, 2026, 20:05 UTC

    Illumina announced its financial results for the second quarter of fiscal year 2026, reporting revenue of $1.16 billion, GAAP operating margin of 21.1%, non-GAAP operating margin of 22.5%, GAAP diluted EPS of $1.35, and non-GAAP diluted EPS of $1.31.

    Source:

  • Jul 28, 2026, 12:00 UTC

    Standard BioTools sold its mass cytometry business to Multiplex Bio, and Illumina bought out contingent payments to advance Standard BioTools' merger with Treeline Biosciences.

    Source:

  • Jul 28, 2026, 00:00 UTC

    Standard Biotools received approximately $30 million cash from Illumina in exchange for waiving its rights to the 2026 Illumina Earnout and agreeing to terminate the existing Royalty and License Agreements between the parties.

  • Jul 16, 2026, 16:00 UTC

    Illumina announced that the Billion Cell Atlas alliance added three new member companies, including Formation Bio.

    Source:

  • Jul 16, 2026, 13:00 UTC

    Juno Bio raised $3.8 million in funding from investors including Ada Ventures, Artesian, Entrepreneur First, and Illumina Accelerator.

    Source:

  • Jul 13, 2026, 07:15 UTC

    Illumina appointed Susan Martin as General Manager for Australia and New Zealand.

    Source:

  • Jul 10, 2026, 06:36 UTC

    Illumina appointed Michael Sullivan as Chief Commercial Officer, effective July 20, 2026, and Julie Coletti as Chief Legal Officer, effective August 3, 2026.

  • Jun 23, 2026, 00:00 UTC

    Daniel M. Skovronsky, M.D., Ph.D. was appointed to the Board of Directors of Illumina, Inc. effective June 16, 2026.

  • Jun 22, 2026, 21:00 UTC

    Fred Alger Management, LLC announced the quarterly rebalancing of the Alger Russell Innovation Index, effective after the close of trading on June 26, 2026, with additions and deletions of several companies.

    Source:

  • Jun 8, 2026, 13:15 UTC

    Illumina launched the StrataMap Spatial Solution, an end-to-end spatial whole transcriptome research solution.

    Source:

  • Jun 1, 2026, 12:58 UTC

    Integrated DNA Technologies announces end-to-end oncology research workflows optimized on Illumina software.

    Source: